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INTRODUCTION
The prevalence rate of antimicrobial resistance to Helicobac-
ter pylori varies with geographical regions, but almost all H.
pylori strains are susceptible to amoxicillin, while 1 to 13% of
strains are resistant to clarithromycin and 20 to 70% of strains
are resistant to metronidazole (1-3). In Korea, the prevalence
rate of metronidazole resistance approaches 50%, but the
clarithromycin resistance rate was reported to be below 5%,
however, has begun to increase recently (4, 5). Therefore the
most widely used primary regimen for H. pylori eradication in
Korea is the triple therapy with clarithromycin, amoxicillin,
and a proton-pump inhibitor. 
The impact of antimicrobial resistance on the eradication
of H. pylori has been reviewed by several investigators (6-8).
The cure rate with metronidazole-based combination regi-
mens in patients with metronidazole-resistant strains was de-
creased by 20 to 50%, compared to patients harboring metro-
nidazole-susceptible strains (6, 7). In case of clarithromycin
resistance, the efficacy of clarithromycin-based triple thera-
py was also decreased by more than 50% (8). Therefore, in
Korea or elsewhere, the clarithromycin resistance is a prime
concern for clinicians who treat the ulcer patients infected
with H. pylori. Clinical microbiology laboratory of Hanyang
University Guri Hospital routinely performs the antimicro-
bial susceptibility testing of H. pylori for clarithromycin since
1996 by the modified broth microdilution method (4). As
culture and susceptibility testing of H. pylori are time- and
labor-demanding procedure, we have tried to develop rapid
detection methods for clarithromycin resistance by molecu-
lar methods. 
Versalovic et al. showed that point mutations in two posi-
tions (A to G at 2142, 2143) in 23S rRNA domain V were
associated with macrolide resistance (9). With appropriate
restriction enzymes (BbsI and BsaI) and the PCR-restriction
fragment length polymorphism (RFLP) technique, Occhialini
et al. developed a relatively simple method detecting these
mutations (10). The aim of this study was to detect the point
mutations in the peptidyltransferase region of 23S rRNA and
to evaluate the molecular method for the detection of clar-
ithromycin-resistant H. pylori isolates from Guri, Korea. 
MATERIALS AND METHODS
Isolation and identification 
H. pylori were isolated from gastric biopsy specimens from
patients diagnosed as peptic ulcer or gastric carcinoma from
1996 through 2001 in Hanyang University Guri Hospital.
Culture was performed on brain heart infusion (BHI) agar
containing 5% sheep blood and the inoculated plates were
Kyung Suk Kim, Jung Oak Kang*, 
Chang Soo Eun
� , Dong Soo Han
� , 
Tae Yeal Choi*
Department of Clinical Pathology, Major Woman's
Hospital; Department of Clinical Pathology* and
Internal Medicine
� , College of Medicine, Hanyang
University, Seoul, Korea
Address for correspondence
Jung Oak Kang, M.D.
Department of Clinical Pathology, Hanyang 
University Guri Hospital, 249-1 Kyomundong, Guri
471-701, Korea 
Tel : +82.31-560-2572, Fax : +82.31-560-2585
E-mail : jokang@hanyang.ac.kr
*This work was supported by a grant from Hanyang
University, Korea, made in the program year of 2001.
599
J Korean Med Sci 2002; 17: 599-603
ISSN 1011-8934
Copyright � The Korean Academy
of Medical Sciences
Mutations in the 23S rRNA Gene of Helicobacter pylori Associated
with Clarithromycin Resistance
Among 12 clarithromycin-resistant Helicobacter pylori strains isolated in Guri, Korea,
8 showed an adenine to guanine mutation at position 2143 (formerly A2144G or
E. coli 2059) in the 23S rRNA gene by the PCR-restriction fragment length poly-
morphism (RFLP) method. The remaining 4 strains, digested by neither BsaI
nor BbsI, showed a thymine to cytosine mutation at position 2182 (T2182C) by
direct sequencing of the PCR products. The T2182C mutants showed a tenden-
cy of higher levels of minimum inhibitory concentration to clarithromycin than the
A2143G mutants. In conclusion, either the A2143G or the T2182C mutation was
present in 100% of clarithromycin-resistant H. pylori isolates examined. The PCR-
RFLP technique with restriction enzymes BbsI and BsaI was a rapid and relative-
ly simple method to detect the clarithromycin resistance. But undigested isolates
were quite frequent among our isolates (33.3%), the PCR-RFLP method with re-
striction enzymes BbsI and BsaI should not be used alone, and development of
other rapid detection method for clarithromycin resistance is mandatory.
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incubated at 37℃ for 3 to 6 days under microaerobic condi-
tions generated by Campy-Pak Plus (BBL Microbiology Sys-
tem, Cockeysville, Md., U.S.A.). Identification was based on
the Gram stain morphology and the presence of oxidase, cata-
lase, and urease activities. 
Antimicrobial susceptibility testing
Minimum inhibitory concentrations (MICs) were deter-
mined by the modified broth microdilution method as de-
scribed by Kim et al. (4). Isolates were subcultured for 72 hr
and saline suspensions of No. 2 McFarland standard were pre-
pared. Serial dilutions of clarithromycin at concentrations rang-
ing from 0.125 to 64 g/mL were prepared in distilled water.
A suspension of each isolate was inoculated into the clarithro-
mycin-containing 96-well microplate. Plates were incubat-
ed at 37℃ for 3 days under microaerobic condition, and the
MIC was recorded as the lowest concentration of the antibi-
otic inhibiting the visible growth of H. pylori. Resistance
was defined as the clarithromycin MIC being ≥1 g/mL
(11). 
Detection of mutations
Genomic DNA was extracted from lysed H. pylori with
InstaGeneTM Matrix (Bio-Rad Lab. Hercules, CA). Two pairs
of PCR primers were used to amplify two fragments of the
peptidyltransferase region of the 23S rRNA. The sequences
of the primers were based on the published sequence of the
23S rDNA gene of H. pylori (GenBank accession number
U27270). Primers K1 (5′ - CCA CAG CGA TGT GGT CTC
AG-3′ corresponding to position 2191 to 2210) and K2 (5′ -
CTC CAT AAG AGC CAA AGC CC-3′ complementary to
position 2596 to 2615) were used to amplify fragment A of
425 bp. Primers K3 (5′ - GCA CAA GCC AGC CTG ACT
G-3′ corresponding to position 2786 to 2804) and K4 (5′ -
AGC AGT TAT CAC ATC CGT G -3′ complementary to
position 3181 to 3199) were chosen to amplify fragment B
of 414 bp (10). 
PCR amplification of DNA was performed in a final vol-
ume of 50  L containing 1  g of H. pylori genomic DNA, 75
mM Tris-HCl (pH 8.8), 20 mM (NH4)2SO4, 0.01% Tween
20, 1.5 mM MgCl2, 0.2 mM concentration of deoxynucleo-
side triphosphate mixture, 1 M concentration of primers
and 2 U of Taq DNA polymerase. The cycling program was
1 cycle at 95℃ for 5 min; 35 cycles of 95℃ for 30 sec, 54
℃for 30 sec, 72℃ for 30 sec; and a final elongation step at
72℃for 10 min. 
The amplified products (fragment A amplicon) were digest-
ed with BbsI and BsaI (New England Biolabs, Inc., Beverly,
Mass., U.S.A.) as described by Occhialini et al. (1997), which
allow discrimination between the wild type, the A2142G
mutant (BbsI restriction site), and the A2143G mutant (BsaI
restriction site). Ten microliters of the amplicon A (425 bp)
was incubated for 24 hr at 56℃ for BsaI and at 37℃ for
BbsI in order to detect the restriction site occurring when the
mutation was A to G at 2143 (formerly 2144) or at 2142
(formerly 2143), respectively. The restriction products were
analyzed by electrophoresis on 2% agarose gel. 
PCR products were purified and concentrated with an aga-
rose gel DNA extraction kit (Roche, Germany). The same
primers for PCR amplification were used for sequencing. Se-
quencing was performed on the two strands of each ampli-
con with an automated DNA sequencer (the ABI PRISM
377XL) and with the sequencing kit (Perkin-Elmer).
RESULTS
Among the 271 clinical isolates of H. pylori from 1996
through 2001, 18 isolates (6.6%) showed clarithromycin re-
sistance. MIC distribution of the 18 clarithromycin-resistant
strains varied from 1  g/mL in 16.7%, 2  g/mL in 5.6%, 4
g/mL in 11.1%, 8  g/mL in 16.7%, 16  g/mL in 5.6%,
32  g/mL in 5.6%, and ≥64  g/mL in 38.9%. Among the
12 resistant isolates that were available for the PCR, BsaI re-
striction enzyme cut the PCR-products of 8 strains to 304
bp and 101 bp bands (Fig. 1), indicating that the 8 strains
had an A to G mutation at position 2143 (A2143G). Nei-
ther BbsI nor BsaI digested the PCR products of remaining
the 4 strains. On sequencing the PCR products of these 4
strains, all four isolates showed a point mutation of T to C
at position 2182 (T2182C). MICs of the A2143G mutant
strains were relatively low from 1 to 8  g/mL, except two iso-
lates (both, ≥64  g/mL). In contrast, MICs of the T2182C
mutants were relatively high from 16  g/mL to ≥64 g/mL
425
304
101
1234567
bp
Fig. 1. Ethidium bromide-stained agarose gel displaying the re-
striction profiles of fragment A (425 bp) treated with BsaI for clar-
ithromycin-resistant H. pylori strains. Lanes 1, 2, 4, 6, and 7 reveal
digestion into 304 bp and 101 bp products, which means an A
to G mutation at position 2143. Lanes 3 and 5; not digested with
either BbsI or BsaI. Sequencing of the PCR products revealed a
T to C mutation at position 2182.(Table 1). 
PCR-RFLP analysis of 14 clarithromycin-susceptible (<
0.5  g/mL) strains of H. pylori showed neither A2142G nor
A2143G mutations. The PCR products of the four isolates
among the 14 undigested clarithromycin-susceptible H. pylori
were sequenced, but disclosed no mutation sites.
DISCUSSION
The clarithromycin resistance is a prime concern for physi-
cians who are using clarithromycin-based triple therapy as a
primary regimen for ulcer patients infected with H. pylori.
Physicians ask for an antimicrobial susceptibility testing for
clarithromycin, but the culture of this fastidious bacterium
takes time and effort, and moreover, antimicrobial suscepti-
bility testing is not practically possible for most clinical micro-
biology laboratories due to its technical difficulty, cost, and
labor. One solution to this problem is offered by the tech-
niques based on PCR. 
Resistance to macrolides is caused by a decrease in binding
of macrolides to the ribosome, which is associated with Erm
methylation of A2058 (Escherichia coli numbering) or muta-
tion at A2058 of 23S rRNA (12, 13). In 1996, Versalovic et
al. first reported the association of clarithromycin resistance
of H. pylori with a single point mutation within the domain
V of 23S r
RNA (9). They identified A to G transition mutations at
positions cognate with Escherichia coli 23S rRNA positions
2058 and 2059, and later named them positions 2143 and
2144 according to the entire H. pylori 23S rRNA sequence by
GenBank no. U27270 (14). Taylor et al. determined the
DNA sequences of the two copies of the 23S rRNA gene from
H. pylori UA802 and compared the sequences from clarithro-
mycin-resistant strains. They defined the 5′ end of the H.
pylori 23S rRNA as position 373 A, and therefore, they pro-
posed that the positions associated with clarithromycin resis-
tance within the H. pylori 23S rRNA be defined as nucleotides
2142 and 2143. Most investigators choose to numerate the
residues 2142 and 2143 according to the definition of the
structure of the 23S rRNA gene in H. pylori published by
Taylor et al. (15). 
The prevalence of mutant strains among the clarithromy-
cin-resistant H. pylori varies in different parts of the world.
Studies from U.S.A. revealed 48% to 53% of A2142G muta-
tion, 39% to 45% of A2143G mutation, and 0% to 7% of
A2142C mutation (14, 16). The prevalence of the A2142G
mutation in Europe was reported as 23% to 33%, A2143G
mutation as 44% to 67%, and A2142C mutation as 2% to
10% (17, 18). However, studies from Japan (19, 20) showed
that more than 90% of the mutant strains had the A2143G
mutation and the A2142C mutation was not detected. Al-
though the number of the strains was small, a study from
China also showed 100% of A2143G mutation in clarithro-
mycin-resistant H. pylori (21).
The incidence of clarithromycin resistance in H. pylori iso-
lated in Korea has been reported below 10%, but the preva-
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97-169 ≥64 A2143G
98-016 8 A2143G
99-100 2 A2143G
99-138 4 A2143G
99-145 8 A2143G
00-150 1 A2143G
01-044 8 A2143G
01-065 ≥64 A2143G
99-084 ≥64 T2182C
99-120 ≥64 T2182C
00-004 16 T2182C
01-045 ≥64 T2182C
96-153 ≥64 Not done
97-025 32 Not done
99-102 4 Not done
00-028 1 Not done
00-028 1 Not done
01-085 1 Not done
Isolates Mutation site Clarithromycin MIC ( g /mL)
Table 1. Minimum inhibitory concentrations (MIC) and mutation
profiles of the clarithromycin-resistant H. pylori isolates 99-084 (R):
HPU27270:
99-084 (R): 
HPU27270:
99-084 (R):
HPU27270:
99-084 (R):
HPU27270:
99-084 (R):
HPU27270:
99-084 (R):
HPU27270:
99-084 (R):
HPU27270:
1
2229
61
2289
121
2349
181
2409
241
2469
301
2529
361
2589
tgtttaccaaaaacacagcactttgccaactcgtaagaggaagtataaggtgtgacgcct 
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
tgtttaccaaaaacacagcactttgccaactcgtaagaggaagtataaggtgtgacgcct 
gcccggtgctcgaaggttaagaggatgcgtcagtcgcaagatgaagcgttgaattgaagc 
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gcccggtgctcgaaggttaagaggatgcgtcagtcgcaagatgaagcgttgaattgaagc
ccgagtaaacggcggccgtaactataacggtcctaaggtagcgaaattccttgtcggtta
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ccgagtaaacggcggccgtaactataacggtcctaaggtagcgaaattccttgtcggtta
aataccgacctgcatgaatggcgtaacgagatgggagctgtctcaaccagagattcagtg
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aataccgacctgcatgaatggcgtaacgagatgggagctgtctcaaccagagattcagtg
aaattgtagtggaggtgaaaattcctcctacccgcggcaagacggaaagaccccgtggac
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
aaattgtagtggaggtgaaaattcctcctacccgcggcaagacggaaagaccccgtggac
ctttactacaacttagcactgctaacgggaatatcatgcgcaggataggtgggaggcttt
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ctttactacaacttagcactgctaatgggaatatcatgcgcaggataggtgggaggcttt
gaagtaagggctt
|||||||||||||
gaagtaagggctt
60
2288
120
2348
180
2408
240
2468
300
2528
360
2588
373
2601
Fig. 2. Nucleotide sequence alignment of the domain V in 23S
rRNA of T2182C mutant strain. The 99-084(R) is a clarithromycin-
resistant H. pylori, of which the MIC is ≥64 g/mL.  Numbering
of nucleotide position followed the proposed system by Taylor et
al. (position 2554-373+1= position 2182). The HPU27270 is the
published sequence of the 23S rRNA gene of H. pylori (GenBank
accession number U27270). The boxed letter indicates T2182C
point mutation.  lence of resistant strains is increasing due to the widespread
use of macrolides as a primary regimen for H. pylori infections
or for the treatment of respiratory tract infection in pediatric
patients (4, 5). Therefore, characterization of the resistance
mechanism in each country will facilitate the development
of a rapid detection method, the choice of appropriate treat-
ment regimens, and ultimately, the control of the infection. 
In our study, all the 12 clarithromycin-resistant strains iso-
lated at Hanyang University Guri Hospital had point muta-
tions at the 23S rRNA gene of H. pylori. The most prevalent
mutation was A2143G (66.7%) and the A2142G mutants
were not identified. Our results are different from those of
Europe or U.S.A. (14, 16-18), but similar with those of Japan
and China where the major type of mutation was reported
as A2143G (19-21). One study from Korea revealed that
A2142G mutation was observed in 87.0%, and A2143G
mutation in 13.0% (22). But in the results of Song et al. (23),
three of four clarithromycin-resistant isolates showed A2143G
mutation and one isolate showed C2215T mutation. In H.
pylori, seven different point mutations (A2142G or C, A2143G
or C, A2115G, G2141A, and A2142T) in the 23S rRNA
gene have been found to be associated with the resistance to
clarithromycin (18, 24). 
Most notable finding of our study is the T2182 to C muta-
tion that has not been reported in H. pylori isolated in Korea.
The A to G transition mutation is presently the most frequent
substitution and has genetic stability and growth advantage
compared to the wild-type strain or to strains with any of
other bases at these positions (17, 25). Also, the A2142G
gives the highest level of resistance to clarithromycin, but
the A2143G mutants have lower levels of clarithromycin
resistance than the A2142G mutants (14). Our results also
showed that the A2143G mutation was related to the low
levels of clarithromycin MICs. Although the underlying
mechanism for this phenomenon has not been known, the
T2182C mutation seems to be associated with high levels of
clarithromycin resistance in H. pylori isolated in Guri, Korea. 
In conclusion, we found a rare mutation site (T2182C)
from the clarithromycin-resistant H. pylori strains isolated
in Guri, Korea. To prove the association of T2182C mutation
with the clarithromycin resistance, further study will be need-
ed. The A2143G mutation was quite frequently observed
(8/12) and the T2182C mutation (4/12) was also observed.
The A2142G mutation was not found in this study. Because
the T2182C mutation was quite frequent among our isolates,
the PCR-RFLP method with restriction enzymes BbsI and
BsaI should not be used alone, and development of other ra-
pid detection method for clarithromycin resistance is manda-
tory.
ACKNOWLEDGMENTS
This work was supported by a grant from Hanyang Uni-
versity, Korea, made in the program year of 2001.
REFERENCES
1. Megraud F, Stuart H, Glupczynski Y. Antibiotic susceptibility and
resistance. In: Mobley HLT, Mendz GL, and Hazell SL, eds. Heli-
cobacter pylori: Physiology and genetics. Washington, DC: ASM
press 2001: 511-30.
2. O’Morain C, Montague S. Challenges to therapy in the future. Heli-
cobacter 2000; 5 (Suppl 1): S23-6.
3. Adamek RJ, Suerbaum S, Pfaffenbach B, Opferkuch W. Primary and
acquired Helicobacter pylori resistance to clarithromycin, metron-
idazole, and amoxicillin- influence on treatment outcome. Am J Gas-
troenterol 1998; 93: 386-9.
4. Kim ES, Kang JO, Han D, Park PH, Park IK, Choi TY. Comparison
of modified broth microdilution method, E test and disk diffusion
method for antimicrobial susceptibility testing of Helicobacter pylori.
Korean J Clin Pathol 1998; 14: 559-64.
5. Kim JJ, Reddy R, Lee M, Kim JG, El-Zaatari FAK, Osato MS, Gra-
ham DY, Kwon DH. Analysis of metronidazole, clarithromycin and
tetracycline resistance of Helicobacter pylori isolates from Korea. J
Antimicrob Chemother 2001; 47: 459-61.
6. Houben MHMG, Van de Beek D, Hensen EF, De Craen AJM, Rauws
EAJ, Tytgat GNJ. A systematic review of Helicobacter pylori eradi-
cation therapy-the impact of antimicrobial resistance on eradication
rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
7. Megraud F, Lehn N, Lind T, Bayerdorffer E, O’Morain C, Spiller
R, Unge P, van Zanten SV, Wrangstadh M, Burman CF. Antimicro-
bial susceptibility testing of Helicobacter pylori in a large multicen-
ter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43:
2747-52.
8. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect
of pretreatment antibiotic resistance to metronidazole and clarithro-
mycin on outcome of Helicobacter pylori therapy: a meta-analytical
approach. Dig Dis Sci 2000; 45: 68-76.
9. Versalovic J, Shortridge D, Kibler K, Griffy MV, Beyer J, Flamm
RK, Tanaka SK, Graham DY, Go MG. Mutations in 23S rRNA are
associated with clarithromycin resistance in Helicobacter pylori.
Antimicrob Agents Chemother 1996; 40: 477-80.
10. Occhialini A, Urdaci M, Doucet-Populaire F, Bebear CM, Lamouli-
atte H, Megraud F. Macrolide resistance in Helicobacter pylori: rapid
detection of point mutations and assays of macrolide binding to ribo-
somes. Antimicrob Agents Chemother 1997; 41: 2724-8.
11. NCCLS document M7-A5. Performance standards for antimicrobial
susceptibility testing: 10th informational supplement (Aerobic dilu-
tion) 2000; 20: M100-S10 p39.
12. Weisblum B. Erythromycin resistance by ribosome modification.
Antimicrob Agents Chemother 1995; 39: 577-85.
13. Vester B, Douthwaite S. Macrolide resistance conferred by base sub-
stitutions in 23S rRNA. Antimicrob Agents Chemother 2001; 45: 1-
12.
14. Versalovic J, Osato MS, Spakovsky K, Dore MP, Reddy R, Stone
GG, Shortridge D, Flamm RK, Tanaka SK, Graham DY. Point muta-
tion in the 23S rRNA gene of Helicobacter pylori associated with dif-
ferent levels of clarithromycin resistance. J Antimicrob Chemother
602 K.S. Kim, J.O. Kang, C.S. Eun, et al.1997; 40: 283-6.
15. Taylor DE, Ge Z, Purych D, Lo T, Hiratsuka K. Cloning and se-
quence analysis of two copies of a 23S rRNA gene from Helicobac-
ter pylori and association of clarithromycin resistance with 23S
rRNA mutations. Antimicrob Agents Chemother 1997; 41: 2621-8.
16. Stone GG, Shortridge D, Versalovic J, Beyer J, Flamn RK, Graham
DY, Ghoneim AT, Tanaka SK. PCR oligonucleotide ligation assay
to determine the prevalence of 23S rRNA gene mutations in clarithro-
mycin-resistant Helicobacter pylori. Antimicrob Agents Chemother
1997; 41: 712-4.
17. Alarcon T, Domingo D, Prieto N, Lopez-Brea M. Clarithromycin
resistance stability in Helicobacter pylori: influence of the MIC and
type of mutation in the 23S rRNA. J Antimicrob Chemother 2000;
46: 613-6.
18. Doorn LJ, Glupczynski Y, Kusters JG, Megraud F, Midolo P, Maggi-
Solca N, Queiroz DMM, Nouhan N, Stet E, Quint WGV. Accurate
prediction of macrolide resistance in Helicobacter pylori by a PCR
line probe assay for detection of mutations in the 23S rRNA gene:
multicenter validation study. Antimicrob Agents Chemother 2001;
45: 1500-4.
19. Maeda S, Yoshida H, Matsunaga H, Ogura K, Kawamata O, Shira-
tori Y, Omata M. Detection of clarithromycin-resistant Helicobac-
ter pylori strains by a preferential homoduplex formation assay. J
Clin Microbiol 2000; 38: 210-4.
20. Kato S, Fujimura S, Udagawa H, Shimizu T, Maisawa S, Ozawa K,
Iinuma K. Antibiotic resistance of Helicobacter pylori strains in Ja-
panese children. J Clin Microbiol 2002; 40: 649-53.
21. Pan ZJ, Su WW, Tytgat GNJ, Dankert H, Ende A. Assessment of
clarithromycin-resistant Helicobacter pylori among patients in Shang-
hai and Guangzhou, China, by primer-mismatch PCR. J Clin Micro-
biol 2002; 40: 259-61.
22. Nam SW, Roe IH, Kim SB, Lee BS, Hwang YJ, Park HJ, Kim JW,
Lee JH, Shin JH, Yu KA. Detection of clarithromycin-resistant
Helicobacter pylori by polymerase chain reaction. Korean J Gas-
troenterol 2000; 36: 450-6. 
23. Song HJ, Chung IS, Kim SW, Lee GM, Kim BW, Lee DS, Yang
YS, Han SW, Park DH, Lee JH. Antimicrobial resistance rates in
Helicobacter pylori and detection of 23S rRNA mutation associated
with clarithromycin resistance. Korean J Gastroenterol 2000; 36:
597-606. 
24. Hulten K, Gibreel A, Skold O, Engstrand L. Macrolide resistance in
Helicobacter pylori: mechanism and stability in strains from clari-
thromycin-treated patients. Antimicrob Agents Chemother 1997; 41:
2550-3.
25. Debets-Ossenkopp YJ, Brinkman AB, Kuipers EJ, Vandenbroucke-
Grauls CMJE, Kusters JG. Explaining the bias in the 23 rRNA gene
mutations associated with clarithromycin resistance in clinical iso-
lates of Helicobacter pylori. Antimicrob Agents Chemother 1998;
42: 2749-51.
Mutations of Helicobacter pylori Associated with Clarithromycin Resistance 603
. . . .